
FDA approves breakthrough pancreatic cancer treatment with doubled survival rates
The story in brief
The FDA approved daraxonrasib, a drug for pancreatic cancer, six months early due to its 'unprecedented results' in a high-unmet-need area. The treatment, sold as Rasonque, targets the mutated KRAS gene in over 90% of pancreatic tumours and nearly doubled survival time in trials, from 6.6 to 13.2 months. The agency called it a 'critical new option' for patients facing a historically hard-to-treat cancer.